Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.

Beleaguered Belgian biotech Galapagos said yesterday that its CEO, Paul Stoffels, plans to retire upon the appointment of his ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

The electric-vehicle maker will report results after markets close. Analysts expect a year-over-year drop in profit, FactSet estimates show. Tesla stock, which has fallen 44% this year through Monday, ...

Shares of Novo Nordisk A/S (NVO) climbed 0.4% on Monday and rose in extended trading after the Danish drugmaker said it had ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...